Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 14, 2005JAMA

Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does ex vivo treatment of vein grafts with edifoligide prevent angiographic vein graft failure in patients undergoing primary CABG surgery?

Population

3014 patients undergoing primary CABG surgery with at least 2 planned saphenous vein grafts and without…

Comparison

Edifoligide vs Placebo

Design

RCT, randomized, double-blind

Follow-up

12 to 18 months

Discussion

Loading...

Member takes

Implication

Edifoligide should not be used for vein graft preservation in CABG; confirms lack of efficacy for E2F decoy therapy in preventing graft failure.

Structured PICO

Does ex vivo treatment of vein grafts with edifoligide prevent angiographic vein graft failure in patients undergoing primary CABG surgery?

P
Population
3014 patients undergoing primary CABG surgery with at least 2 planned saphenous vein grafts and without concomitant valve surgery
I
Intervention
Edifoligide (ex vivo treatment of vein grafts in a pressure-mediated delivery system)
C
Comparator
Placebo (ex vivo treatment of vein grafts in a pressure-mediated delivery system)
O
Outcome
Angiographic vein graft failure (≥75% vein graft stenosis) occurring 12 to 18 months after CABG surgerysurrogate

Ex vivo treatment of saphenous vein grafts with the E2F transcription factor decoy edifoligide does not reduce the incidence of angiographic vein graft failure 12 to 18 months after CABG surgery.

Cite This Study

A 2005 study studied this question.

synapsesocial.com/papers/6a8718566fbb37794f7cb76ahttps://doi.org/10.1001/jama.294.19.2446
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aortocoronary Saphenous Vein Graft Disease1998 · 1,083 citations
  2. 2Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial2000 · 275 citations
  3. 3Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts.1994 · 115 citations
  4. 4The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts1997 · 972 citations
  5. 5A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.1995 · 482 citations